Updated: 4 days ago
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
You may have heard the words CAR-T therapy after several rounds of treatment for lymphoma, leukaemia or multiple myeloma. Then comes the difficult part: finding out whether it is actually available to you in New Zealand, whether you qualify for a clinical trial, and what alternatives exist if you do not.
For New Zealand families, this can be especially confusing because CAR-T is developing locally while China already has several NMPA-approved CAR-T products for specific indications. That does not make one country automatically better. The right option depends on your cancer, treatment history, eligibility and what treatment pathway is realistically available to you.
This guide explains CAR-T therapy in New Zealand, what is currently happening through the NZ clinical-trial system, how China's approved CAR-T pathways differ, and what you should check before considering treatment overseas.
Key Takeaways |
|
What is the CAR-T Pathway in New Zealand Right Now?
CAR-T is not a single medicine. It is a form of immunotherapy in which a patient's T cells are collected and genetically modified so they can recognise and attack cancer cells. The modified cells are then returned to the patient.
It has shown important results in certain blood cancers, particularly some lymphomas, B-cell leukaemias and multiple myeloma. But the treatment is complex and can cause serious complications, so it requires specialised clinical infrastructure and monitoring.
In New Zealand, the most visible CAR-T pathway is currently the Malaghan Institute's clinical-trial programme.
The ENABLE-2 phase 2 trial is testing a locally manufactured CAR-T therapy for certain types of lymphoma. Malaghan reports that the trial began in July 2024 and involves treatment in Auckland, Wellington and Christchurch.
The important distinction is clinical trial versus routine treatment.
Being treated through a trial is not the same as being able to request an approved commercial CAR-T product through the normal health system. Trial participation has its own eligibility requirements and requires referral through an appropriate specialist. Malaghan specifically advises patients to speak with their haematologist or oncologist about whether ENABLE-2 or another clinical trial may be suitable.
New Zealand is also developing its regulatory framework. In September 2026, Medsafe's Medicines Classification Committee agenda included consideration of a group entry for CAR-T therapies as prescription medicines.
That is evidence of an evolving regulatory environment, not evidence that every commercial CAR-T product is currently routinely available in New Zealand.
Which New Zealand Patients May Be Able to Access CAR-T?
Eligibility is much narrower than simply having a blood cancer.
The specific cancer matters. So does the target on the cancer cell, previous treatment, whether the disease has relapsed or become resistant, and the patient's general condition.
For example, the New Zealand ENABLE-2 programme is focused on certain types of lymphoma rather than all blood cancers.
A patient with multiple myeloma should therefore not assume that a lymphoma-focused New Zealand trial is an appropriate pathway. Similarly, someone with acute leukaemia should not assume that a CAR-T programme designed around a particular lymphoma applies to them.
Your haematologist may consider:
the exact diagnosis and subtype
stage or disease status
previous lines of treatment
response or resistance to previous therapies
relevant biomarkers or antigen expression
organ function
infection status
overall ability to tolerate intensive treatment
whether you meet the specific trial or product criteria
This is why an online list of CAR-T products is not enough to determine whether you are a candidate.
The treatment needs to be matched to the biology of your cancer and your individual clinical history.
What CAR-T Options are Available in China?
China has developed a substantial CAR-T treatment and manufacturing ecosystem, and the country's National Medical Products Administration (NMPA) has approved multiple CAR-T products.
For example, equecabtagene autoleucel was approved with conditions by China's NMPA for adults with relapsed or refractory multiple myeloma after three or more prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
China's NMPA also approved ciltacabtagene autoleucel (Carvykti) with conditions for adults with relapsed or refractory multiple myeloma after three or more prior lines of therapy and progression, including prior treatment with a proteasome inhibitor and an immunomodulatory agent.
These examples illustrate an important point about CAR-T availability in China.
“CAR-T is available in China” does not mean every CAR-T product is available for every blood cancer.
Each product has a defined indication and eligibility criteria. A hospital still needs to assess the patient's records before deciding whether a particular treatment is appropriate.
China also has ongoing research into newer CAR-T approaches and other blood-cancer applications. Clinical-trial availability changes frequently, so any claim that a particular trial is recruiting international patients should be checked directly with the relevant hospital or trial registry before travel.
How Does Treatment in China Differ From The New Zealand Pathway?
The biggest difference for a patient is often the type of access pathway being considered.
In New Zealand, a patient may be considered for an appropriate clinical trial such as ENABLE-2, subject to the trial's eligibility and referral process. The programme is designed to build domestic capability and eventually support broader access to CAR-T in New Zealand.
In China, there are already NMPA-approved CAR-T products for specific indications, alongside clinical research.
That creates a different question for a New Zealand patient:
Is there an approved CAR-T product in China that matches my exact cancer and treatment history?
That is a much more useful question than simply asking whether China “has CAR-T”.
There is also a practical difference. Travelling overseas means dealing with international medical records, language, accommodation, flights, visa requirements, payment arrangements and the handover back to your New Zealand medical team.
China can therefore offer an additional treatment pathway, but it also creates additional responsibilities for the patient and family.
Is CAR-T Funded in New Zealand?
This is one of the areas where you should be careful with older online information.
Pharmac is responsible for decisions about which medicines and related products are funded in Aotearoa New Zealand. Health New Zealand provides cancer treatment and care. The cancer treatment system is also evolving, with the 2026–2029 Cancer Action Plan identifying timely diagnosis and treatment and access to modern therapies as priorities.
Pharmac's 2026 reporting also specifically refers to work on advanced cellular therapies, including CAR-T therapies, as part of planning for emerging medicines and technologies.
At the same time, funding decisions are indication-specific. A medicine can be funded for one condition or use and not funded for another.
Pharmac explains that an application is a request to fund a medicine for a specific condition, and that funding applications can be declined while potentially being reconsidered if new information becomes available.
For that reason, there is no reliable blanket statement such as “CAR-T is funded in New Zealand” or “CAR-T is not funded in New Zealand” that applies to every patient.
If you are not eligible for a New Zealand trial or funded pathway, that does not automatically mean treatment overseas is appropriate. It means you may want to investigate what other options exist.
What Are The Risks Of CAR-T, Wherever I Receive it?
CAR-T is a serious cancer treatment, not a low-risk alternative simply because it may be available in another country.
One of the recognised complications is cytokine release syndrome (CRS), an inflammatory reaction that can range from mild to severe.
Another is immune effector cell-associated neurotoxicity syndrome (ICANS). Medsafe notes that CAR-T therapies are among the treatments most commonly associated with ICANS, and severe cases can be life-threatening.
Other complications can include prolonged low blood counts, infections and other immune-related problems.
This is why the hospital's monitoring capability matters.
Before travelling, ask:
Where will the patient be monitored after infusion?
How long is inpatient observation expected to last?
What happens if CRS or neurological toxicity develops?
Is intensive-care support available if required?
How long does the treating team recommend staying in China?
Who should the family contact after returning to New Zealand?
A treatment should not be judged only by the product name or price.
The ability to manage complications is part of the treatment.
What If CAR-T Is Not Available To Me In New Zealand?
This is where the decision becomes individual.
Your first step should be to establish why CAR-T is not currently available to you.
It could be because:
your cancer does not match the indication
you do not meet the trial criteria
the relevant product is not available
your previous treatment history makes you ineligible
your current health makes CAR-T unsafe
there is another treatment your oncologist considers more appropriate
Sometimes the answer is simply that CAR-T is not the right treatment.
If your medical team believes CAR-T may be appropriate but you cannot access a relevant pathway in New Zealand, then an overseas assessment can be a reasonable next question.
China is one possible destination to investigate because of its established CAR-T treatment and manufacturing programmes. But the case still needs to be reviewed against the specific Chinese product and hospital pathway.
ChinaCureLink can help at this stage by reviewing the patient's medical records before travel and determining whether there appears to be a relevant treatment pathway worth discussing with a Chinese hospital.
The aim is not to persuade a family to travel.
It is to find out whether there is something concrete to investigate.
What Should I Compare Before Choosing New Zealand or China?
The most useful comparison is not simply “Which country has better CAR-T?”
Instead, compare the actual pathways available to you.
Question | New Zealand | China |
Is there a relevant CAR-T pathway? | Depends on diagnosis and current trial/regulatory access | Depends on the specific NMPA-approved product or trial |
Is the patient eligible? | Trial/product criteria apply | Product and hospital criteria apply |
Where is treatment delivered? | Current clinical-trial programmes include NZ sites | Hospital-specific |
Is treatment publicly funded? | Depends on current Pharmac decisions and eligibility | Overseas treatment generally requires private payment unless another arrangement applies |
What happens after treatment? | Local follow-up may be easier | Handover to NZ oncology team needs planning |
Travel required? | No for NZ treatment | Yes |
Language/translation | Usually straightforward | Needs planning |
Total financial commitment | Depends on pathway | Includes treatment plus international travel/living costs |
This table is not a recommendation for one country.
It is a reminder that the “right” comparison is between your actual available pathways, not between two abstract healthcare systems.
For some patients, a New Zealand clinical trial may be the most relevant route. For others, a Chinese hospital may have an approved CAR-T product that matches their specific diagnosis. For others, neither option may be appropriate.
How ChinaCureLink Can Help New Zealand Patients with CAR-T Therapy
If you have been told that CAR-T may be appropriate but cannot see a clear pathway in New Zealand, the first problem is usually uncertainty: Am I eligible, which CAR-T product applies to me, and what would treatment in China actually involve?
ChinaCureLink can start with a review of your medical records to assess whether your case may be suitable for a CAR-T pathway in China. Hospital and specialist matching is based on your diagnosis, biomarkers and treatment history rather than simply choosing a hospital from a ranking list.
If a potential pathway is identified, your records can be translated and a remote video consultation arranged before you travel. This gives the treating team an opportunity to discuss the proposed CAR-T treatment, eligibility, risks and practical requirements.
Before you commit, ChinaCureLink can coordinate a written treatment plan and itemised cost estimate so you can understand the medical costs alongside the separate costs of travel and accommodation.
If you decide to proceed, coordination can include visa, flight, accommodation and airport-transfer arrangements, with a dedicated care manager and professional medical interpreters during consultations.
After treatment, ChinaCureLink can coordinate a translated discharge packet for your New Zealand oncologist and provide follow-up support after you return.
You can investigate the option before making a commitment to overseas treatment.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Frequently Asked Questions
Is CAR-T therapy available in New Zealand?
New Zealand currently has a CAR-T clinical-trial programme. The Malaghan Institute's ENABLE-2 phase 2 trial is testing a locally manufactured CAR-T therapy for certain lymphomas. Routine access and funding are separate questions and depend on the product, indication and current regulatory and funding decisions.
Can New Zealand patients get CAR-T treatment in China?
Some New Zealand patients may be able to receive CAR-T in China if they meet the eligibility requirements for a relevant product and are accepted by the treating hospital. China has NMPA-approved CAR-T products for specific blood-cancer indications. Eligibility must be assessed from the patient's medical records before travel.
Is CAR-T funded in New Zealand?
CAR-T funding should be checked against the patient's exact diagnosis and treatment pathway. Pharmac makes funding decisions for medicines and related products, while the regulatory and clinical-trial landscape for CAR-T continues to develop. Do not assume that a funding statement about one CAR-T product applies to every indication.
Which cancers can CAR-T treat?
CAR-T is currently established mainly for certain blood cancers, including some lymphomas, B-cell leukaemias and multiple myeloma. Different CAR-T products target different cancers and have specific eligibility criteria. Having blood cancer does not automatically mean CAR-T is an appropriate treatment.
Is CAR-T in China approved?
China's NMPA has approved several CAR-T products for defined indications. For example, equecabtagene autoleucel and ciltacabtagene autoleucel have approvals for specified relapsed or refractory multiple-myeloma populations. Approval applies to the specific product and indication; it does not mean CAR-T is approved for every cancer.
Should I travel to China for CAR-T treatment?
Travel should only be considered after your specific case has been assessed. The relevant questions include whether you meet the product's criteria, whether the hospital accepts your case, what treatment and monitoring are required, the total cost, and how follow-up will be managed after you return to New Zealand.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
References
Malaghan Institute — CAR T-cell cancer immunotherapy and ENABLE-2 clinical trial programme Malaghan Institute CAR-T programme
Malaghan Institute — ENABLE-2 reaches midway milestone, April 2026 ENABLE-2 clinical trial update
Medsafe — 2026 Medicines Classification Committee agenda, CAR-T therapies Medsafe CAR-T classification agenda
Pharmac — Cancer treatments and funding information Pharmac funding process
Health New Zealand — Cancer treatments Health New Zealand cancer treatments
Health New Zealand / Te Aho o Te Kahu — New Zealand Cancer Action Plan 2026–2029 New Zealand Cancer Action Plan 2026–2029
China NMPA — Equecabtagene Autoleucel approval China NMPA: Equecabtagene autoleucel
China NMPA — Ciltacabtagene Autoleucel approval China NMPA: Ciltacabtagene autoleucel
Medsafe — Immune effector cell-associated neurotoxicity syndrome (ICANS) Medsafe: ICANS and CAR-T therapy
Comments